Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > July 2006 - Volume 65 - Issue 7 > Involvement of Oxidative Stress in Alzheimer Disease
Text sizing:
A
A
A
Journal of Neuropathology & Experimental Neurology:
doi: 10.1097/01.jnen.0000228136.58062.bf
Review Article

Involvement of Oxidative Stress in Alzheimer Disease

Nunomura, Akihiko MD, PhD; Castellani, Rudy J. MD; Zhu, Xiongwei PhD; Moreira, Paula I. PhD; Perry, George PhD; Smith, Mark A. PhD

Free Access
Article Outline
Collapse Box

Author Information

From the Department of Psychiatry and Neurology (AN), Asahikawa Medical College, Asahikawa, Japan; the Department of Pathology (RJC), University of Maryland, Baltimore, MD; the Department of Pathology (XZ, GP, MAS), Case Western Reserve University, Cleveland, OH; the Center for Neuroscience and Cell Biology of Coimbra (PIM), University of Coimbra, Coimbra, Portugal; and the College of Sciences (GP), University of Texas at San Antonio, San Antonio, TX.

Send correspondence and reprint requests to: Mark A. Smith, PhD, Department of Pathology, Case Western Reserve University, 2103 Cornell Road, Cleveland, OH 44106; E-mail: mark.smith@case.edu

Work in the authors' laboratories is supported by funding from Japan Society for the Promotion of Science (AN), the National Institutes of Health, the Alzheimer's Association, and Philip Morris USA, Inc. and Philip Morris International.

Collapse Box

Abstract

Genetic and lifestyle-related risk factors for Alzheimer disease (AD) are associated with an increase in oxidative stress, suggesting that oxidative stress is involved at an early stage of the pathologic cascade. Moreover, oxidative stress is mechanistically and chronologically associated with other key features of AD, namely, metabolic, mitochondrial, metal, and cell-cycle abnormalities. Contrary to the commonly held notion that pathologic hallmarks of AD signify etiology, several lines of evidence now indicate that aggregation of amyloid-β and tau is a compensatory response to underlying oxidative stress. Therefore, removal of proteinaceous accumulations may treat the epiphenomenon rather than the disease and may actually enhance oxidative damage. Although some antioxidants have been shown to reduce the incidence of AD, the magnitude of the effect may be modified by individual factors such as genetic predisposition (e.g. apolipoprotein E genotype) and habitual behaviors. Because caloric restriction, exercise, and intellectual activity have been experimentally shown to promote neuronal survival through enhancement of endogenous antioxidant defenses, a combination of dietary regimen of low total calorie and rich antioxidant nutrients and maintaining physical and intellectual activities may ultimately prove to be one of the most efficacious strategies for AD prevention.

Back to Top | Article Outline

INTRODUCTION

The process of neurodegeneration in Alzheimer disease (AD) is a dynamic, multifaceted biochemical phenomenon and is essentially lifelong. Symptomatic disease, on the other hand, although more easily recognized and more easily diagnosed pathologically, represents the end stage. The simple fact that senile plaques and neurofibrillary tangles (NFTs) can be seen with a light microscope should not imply etiology, yet the primacy of these lesions in terms of disease pathogenic theories, and the de facto reliance on them to assess animal models and response to therapy, suggests otherwise. Too little attention is paid to early, presymptomatic biochemistry, both in terms of furthering knowledge of pathogenesis and targeting therapy. Targeting measurable but manifestly end-stage lesions such as senile plaques and NFTs may not only be ineffective, but may accelerate the disease.

Oxidative stress, on the other hand, has been shown in numerous studies to precede the cardinal neuropathologic manifestations of AD. Oxidative modifications are further seen in cerebral tissue in early stages of AD, whereas oxidation of nucleic acids, proteins, and lipids are all prominent and early changes in AD, and oxidatively modified macromolecules are present in biologic fluids from the patients with AD as well as cellular and animal AD models (reviewed in [1]).

Accompanying oxidative insults are attempts at apoptosis and regeneration, both as early phenomena before the formation of senile plaques and NFTs. The attempt at apoptosis is incomplete or "abortive" (2), and this makes mechanistic sense given the evanescent time interval over which apoptosis occurs in general. Similarly, attempts at regeneration by diseased neurons, or cell-cycle reentry, which is a pervasive and early change in the AD brain (3, 4), is ineffective and likely predisposes diseased neurons to further degeneration.

Evidence is accumulating that the end-stage lesions in AD, namely senile plaques and NFTs, are a fundamental adaptive, rather than deleterious, response. The adaptive nature is evidenced by the sequestration of redox-active metals by senile plaques and intraneuronal inclusions (5-9) and the increasing recognition that inclusion-bearing neurons are generally protected from immediate cell death (10-12). In the context of chronic neurodegeneration in AD, therefore, the idea of removal of end-stage lesions as a viable treatment option remains dubious in our view, whereas intervention that targets fundamental early changes such as oxidative stress and aberrant cell-cycle reentry is manifestly more logical.

Back to Top | Article Outline
Genes and Risk Factors Associated With Alzheimer Disease Are Intimately Implicated in Oxidative Stress

The prevalence of AD increases exponentially throughout aging with approximately half of the population afflicted by the age of 95 (13), suggesting that advanced age is a major risk factor for AD. Like in other organ systems, cells in the brain encounter a cumulative burden of oxidative and metabolic stress that may be a universal feature of the aging process as well as a major causal factor of senescence. Moreover, the brain is especially vulnerable to free radical damage because of its high content of easily peroxidizable unsaturated fatty acids, high oxygen consumption rate (accounting for 20-25% of the total body oxygen consumption, but for less than 2% of the total body weight), and relative paucity of antioxidant enzymes compared with other organs (e.g. the content of catalase in brain is only 10-20% of liver and heart) (14-16).

Germline mutations leading to familial, early-onset AD are also oxidative stress-causing mutations. Elevated vulnerability to oxidative stress-induced cell death and/or reduced antioxidant defenses have been demonstrated in: 1) cell lines expressing mutant human amyloid β protein precursor (AβPP), presenilin-1 (PS-1), or presenilin-2 (PS-2) (17-20); 2) transgenic mice expressing mutant human AβPP and/or PS-1 as well as knock-in mice expressing mutant human PS-1 (21-28); 3) fibroblasts and lymphoblasts from patients with familial AD with AβPP or PS-1 gene mutations (29); and 4) cerebral cortex of autopsied brain samples from patients with AβPP or PS-1 gene mutations (30, 31). Moreover, the possession of one or both apolipoprotein E (APOE) ϵ4 alleles, a major genetic risk factor for late-onset familial and sporadic AD (32), is associated with oxidative stress. In vitro, APOE shows allele specific antioxidant activity, with APOE ϵ2 the most effective and APOE ϵ4 being the least effective (33). Oxidative damage in an APOE genotype-dependent manner has been further demonstrated in autopsy brain samples of AD (34-36).

Medical risk factors for AD include traumatic brain injury, stroke, hypertension, diabetes mellitus, hypercholesterolemia, and hyperhomocystinemia (37-41). Environmental and lifestyle-related risk factors for AD include aluminum exposure, smoking, high calorie intake, lack of exercise, and lack of intellectual activities (42-45). As it turns out, all these risk factors are associated with an increase in production and propagation of reactive oxygen species and/or a decrease in endogenous antioxidant capacity (14, 46-51). Similarly, nutrients or agents inhibiting free radical formation reduce the incidence of AD. This includes not only the free radical scavenging vitamins C and E (52), but also estrogen, nonsteroidal antiinflammatory drugs, statins, omega-3 polyunsaturated fatty acids, and red wine (53-57), all of which show antioxidant activities (58-62). Furthermore, calorie restriction, exercise, and intellectual activity have been shown to promote neuronal survival through an enhancement of endogenous antioxidant defenses in experimental animals (14, 63).

Germline mutations and risk factors for AD that cause or promote oxidative damage as well as agents, nutrients, and behavior that prevent or attenuate oxidative damage are summarized in Table 1. Overall, the data indicates that oxidative stress is intimately associated with the pathogenesis of AD and acts "upstream" of the pathologic process.

Table 1
Table 1
Image Tools
Back to Top | Article Outline
Oxidative Stress Is an Early and Prominent Feature of Alzheimer Disease

The early involvement of oxidative stress in AD is demonstrated by recent studies on cell culture models, transgenic animal models, postmortem brains, and biologic fluids from subjects with AD, mild cognitive impairment (MCI), and Down syndrome (Tables 2 and 3). Using an in situ approach to identify markers of nucleic acid and protein oxidation in human brain, we found that oxidative damage is more pronounced in AD subjects with lesser amounts of Aβ deposition or AD subjects with shorter disease duration (64). Furthermore, we found that oxidative damage precedes Aβ deposition in brain tissue from Down syndrome, a putative model of AD with predictable neuropathologic progression over time (65). These findings are consistent with the increased nucleic acid oxidation in cerebrospinal fluid from AD subjects, in which the shorter the disease duration, the greater the oxidative damage (66). Moreover, individuals with MCI or very mild AD show: 1) increased levels of lipid peroxidation and nucleic acid oxidation in postmortem brain tissue (67, 68) (Fig. 1); 2) increased levels of lipid peroxidation and nucleic acid oxidation in cerebrospinal fluid, plasma, urine, and peripheral leukocytes (69, 70); and 3) decreased levels of plasma antioxidants and total plasma antioxidant capacity (71, 72). Upregulation of heme-oxygenase-1, a sensitive marker of oxidative stress, is observed in astroglial cells in postmortem brains of AD and MCI (73).

Table 2
Table 2
Image Tools
Table 3
Table 3
Image Tools
Figure 1
Figure 1
Image Tools

The human data is supported by the experimental studies using cell culture and transgenic animal models of AD. Increased lipid peroxidation and protein oxidation and decreased copper/zinc superoxide dismutase (SOD) activity precede Aβ plaque deposition or Aβ fibril formation in transgenic mouse and C. elegans models of AD amyloidosis (23, 74, 75). Oxidative stress induces intracellular Aβ accumulation and tau phosphorylation in cell cultures (76-78), and vitamin E reduces Aβ and tau lesions in transgenic animals (79, 80). Furthermore, dietary copper stabilizes brain copper/zinc SOD activity and reduces Aβ production in AβPP transgenic mice (81). AβPP mutant mice crossed with manganese SOD heterozygous knockout mice show increased Aβ plaque deposition in brain (82). The early involvement of oxidative stress in the pathologic cascade of AD is likely to be closely associated with other key features of AD such as metabolic dysfunction, mitochondrial dysfunction, metal dysregulation, and cell-cycle dysregulation (reviewed in [83]). In fact, all these features are observed as early-stage events of AD, which are shown in human (3, 84-86) and transgenic animal models (4, 87-89). In short, oxidative stress not only is an upstream event, but also has been shown to play a fundamental, direct role in the pathogenesis of AD by a variety of mechanisms.

Back to Top | Article Outline
The Pathology of Alzheimer Disease May Represent a Response to Oxidative Stress

Neuropathologic assessment is a means of definitive diagnosis of patients with dementia and establishes benchmarks by which models of neurodegenerative diseases are validated. Nevertheless, because the diagnosis of AD rests in the semiquantitative association of lesions with a known clinical phenotype (rather than the presence or absence of lesions), it remains an open question whether the basic pathology of AD represents effect rather than cause or response to injury rather than injury per se. Likewise, evidence that neurodegenerative inclusions are epiphenomenal, or even protective, is accumulating. In a cellular model of Huntington disease, a neurodegenerative disorder caused by an abnormal polyglutamine expansion, the formation of neuronal intranuclear inclusions was associated with improved neuronal survival and decreased levels of mutant huntingtin protein throughout the neuron (12). Similarly, recent studies indicate that toxic oligomers or protofibrils of Aβ are responsible for cell death and that the fibrillar Aβ in typical amyloid plaques may actually be neuroprotective (reviewed in [90, 91]). These findings further support our previous studies demonstrating the sequestration of heavy metals by pathologic inclusions (5, 7-9) and the general concept that neurodegenerative disease pathology fundamentally represents the response to the disease process as is the case for other amyloids.

It is noteworthy that senile plaques and NFTs are present in a considerable percentage of brains of cognitively normal elderly subjects, often in large numbers. A study investigating autopsied subjects aged between 69 and 100 who were cognitively intact revealed that 49% of those normal subjects met the Khachaturian criteria for AD based on senile plaque density, 25% met the CERAD criteria for "definite" AD based on senile plaque density, and 24% were Braak stages IV-VI (92). Although uncommon, the presence of Braak stage VI AD in occasional cognitively intact elderly individuals should highlight the limited role AD pathology plays in etiology (92). Furthermore, the poor correlation between neuronal loss and senile plaque density as well as between disease severity and senile plaque density in AD is well known (93). Accordingly, AβPP transgenic mice showing massive deposition of Aβ plaques in brains lack consistent, widespread neuronal loss (94). By contrast, neuronal loss and clinical severity correlate with NFT density, with the amount of neuronal loss exceeding the amount of NFTs (95, 96). In a tau transgenic mouse, in which the overexpression of mutant human tau can be regulated by tetracycline, turning off tau expression halts neuronal loss and reverses memory defects. However, surprisingly, in this model, NFTs continue to accumulate (97). This is consistent with a report on transgenic mice expressing nonmutant human tau, in which neuronal death occurs independently of NFT formation (4). In an ultrastructural study of human tissue, a reduction in number and total length of microtubules in pyramidal neurons in AD was unrelated to the presence of NFTs (98). In contrast, neurons with NFTs are estimated to be able to survive for decades (10), indicating that NFTs themselves are not obligatory for neuronal death in AD. Given these data, and that oxidative stress precedes structural (pathologic) alterations, it appears more and more that the pathology is not only nonetiologic, but a compensatory phenomenon to the fundamental oxidative injury that drives neuronal death in AD (Fig. 2).

Figure 2
Figure 2
Image Tools

Although high concentrations of Aβ in the micromolar range can lead to oxidative stress in various biologic systems (reviewed in [99]), it is apparent from cell (76, 77), animal (23, 74, 75, 80-82), and human (65) studies that oxidative stress chronologically precedes Aβ deposition. Moreover, increased density of Aβ plaque deposition is associated with decreased levels of nucleic acid oxidation in neurons in postmortem brains from patients with sporadic and familial AD and Down syndrome (30, 64, 65). These findings indicate that the process of Aβ plaque formation is linked to neuronal protection against oxidative stress. Recently, in vitro and in vivo studies have demonstrated an antioxidant activity of Aβ. Monomeric Aβ1-40 and Aβ1-42 has been shown to protect cultured neurons from iron and copper-induced toxicity (100). In concordance with this, coinjection of iron and Aβ1-42 into rat cerebral cortex is significantly less toxic than injection of iron alone (101). Furthermore, addition of physiological concentrations (in a low nanomolar range) of Aβ1-40 and Aβ1-42 has been shown to protect lipoproteins from oxidation in cerebrospinal fluid and plasma (99). These Aβ peptides fail to prevent metal-independent oxidation and Aβ25-35 lacking the metal-binding site located in N-terminal domain (histidine at positions 6, 13, and 14 and tyrosine at position 10) is less effective at inhibiting oxidation. Therefore, it is likely that the mechanism by which Aβ inhibits oxidation is through chelating metal ions (99). Indeed, copper, iron, and zinc are elevated in the rims and cores of Aβ plaques in postmortem brains of AD (6, 9). We propose that chelation of redox-active copper and iron is a most important mechanism in the protective function of Aβ and that elevation of zinc, a redox-inert antioxidant, may be a homeostatic response to oxidative stress, which subsequently accelerates the formation of Aβ plaques (102).

The findings that Aβ actually plays an important role in antioxidant defenses may equally apply to tau. Cellular (78), animal (79), and human (65) studies suggest that oxidative stress chronologically precedes NFT formation. Oxidative stress activates several kinases, including glycogen synthase kinase-3 and mitogen-activated protein kinases, which are activated in AD and are capable of phosphorylating tau. Once phosphorylated, tau becomes particularly vulnerable to oxidative modification and consequently aggregates into fibrils (reviewed in [103-105]). Therefore, NFT formation is likely to be a result of neuronal oxidation, which is accompanied by an induction of an antioxidant enzyme heme oxygenese-1 (105). In fact, in postmortem brains of AD, neuronal oxidative damage to nucleic acid is actually decreased by the presence of NFTs when neurons with NFTs are compared with neurons free of NFTs (64). Although the exact mechanism by which NFT formation opposes to oxidative stress is unknown, redox-active iron accumulation is strikingly associated with NFTs (5) and tau is capable of binding to iron and copper by which it may exert antioxidant activities (8).

As we have reviewed here, the disease-specific proteins, Aβ and tau, potentially play a protective role against oxidative stress. However, the efficiency of the protective function may be dependent on the aggregation state of the protein (100). An increasing body of evidence has been collected to support the hypothesis that oligomers, not monomers or fibrils, are the toxic fraction of the protein (reviewed in 90, 91). Therefore, further study is required to adequately assess the relationship between oxidative stress and oligomer formation, which may provide an important clue to successful early therapeutic intervention in AD.

Back to Top | Article Outline
Antioxidant Strategy for Alzheimer Disease: Lessons From Vitamin E Studies

Approaches to treatment during different stages of AD can be divided as primary prevention for asymptomatic population, secondary prevention for subjects with MCI, and symptomatic treatment for patients with AD (106). Antioxidant defenses are classified into three groups, namely, 1) the preventive antioxidants such as SOD, glutathione peroxidase, and metal chelating proteins; 2) the radical-scavenging antioxidants such as vitamins C and E; and 3) the repair and de novo enzymes such as lipase, protease, and DNA repair enzymes (107). A metal-chelating agent, clioquinol (108), and radical-scavenging antioxidants (52, 109-111) have been proposed for reducing the risk of AD and/or slowing the progression of AD. In particular, vitamin E has been frequently tested in prospective epidemiologic studies and clinical trials, and the data for vitamin E are presently available for primary and secondary prevention (52, 110-114) and symptomatic treatment for AD (109).

Vitamin E is the most important lipid-soluble chain-breaking natural antioxidant in mammalian cells and is able to cross the blood-brain barrier and accumulate at therapeutic levels in the brain, where it reduces lipid peroxidation (115). In a cross-sectional study of 4,809 elderly patients, decreasing serum levels of vitamin E per unit of cholesterol were consistently associated with decreasing levels of memory, whereas serum levels of vitamins A and C, β-carotene, and selenium were not associated with poor memory performance (116). An association of vitamin E intake with better cognitive function in the elderly has been found in large cohort studies. In the Honolulu-Asia Aging Study of 3,385 men aged 71 to 93 years, supplementary intake of either vitamin C or E was associated with better cognitive function (117). The Chicago Health and Aging Project with samples of 2,889 community residents aged 65 to 102 years found that supplementary or dietary intake of vitamin E, but not vitamin C, or carotenes was inversely related to cognitive decline (118). In the Nurses' Health Study of 14,968 women aged 70 to 79 years, long-term and current users of supplements containing vitamins C and E had better cognitive function (119).

However, data from prospective studies relating intake of vitamin E and risk of AD are conflicting. Among recent prospective cohort studies summarized in Table 4, the Rotterdam study was performed with the largest sample size and found that dietary intake of vitamin E was associated with a low risk of AD (52). This association was more prominent among current smokers and did not vary by APOE genotype, excluding supplement users, or controlling for supplement use. The Chicago Health and Aging Project found that dietary, but not supplementary, intake of vitamin E was associated with a low risk of AD only among noncarriers of the APOE ε4 allele (110). In the Washington Heights-Inwood Columbia Aging Project, however, no association was found between dietary or supplementary intake of vitamin E and a decreased risk of AD (112). Although the Cache Country Study also demonstrated no beneficial effect of supplementary intake of vitamin E alone on reduction in risk of AD, it found an association between a combined supplementary intake of vitamins C and E and a reduced risk of AD (111). The Honolulu-Asia Aging Study of elderly men with higher age range (71-93 years) found an association between a combined supplementary intake of vitamins C and E and a reduced risk of vascular dementia but not AD (117). The same study group also examined the midlife dietary intake of antioxidants and risk of late-life dementia, in which men aged 45 to 68 years at enrollment were followed up for approximately 30 years. Dietary intake of vitamin C, vitamin E, β-carotene, or flavonoids was not associated with a reduced risk of dementia or its subtype (113). Only the Rotterdam study found a beneficial effect of dietary intake of vitamin C alone on reduction in risk of AD, which was more prominent among current smokers. In this study, β-carotene or flavonoids showed a similar effect only among current smokers (52). In summary, the results to date are really inconsistent. However, they may suggest the importance of having a balanced combination of several antioxidant nutrients to exert a significant effect on the prevention of AD. Intake of the nutrients from foods is preferable to that from supplements in some studies, indicating that a sufficient intake of a certain nutrient from food may reflect well-balanced intake of other nutrients that are important for its absorption and/or biologic activity (120). Even if antioxidant nutrients are taken in an appropriate way, their effects may be modified by individual factors such as genetic predisposition (e.g. APOE genotype) and habitual behavior such as smoking. Recently, in a double-blind, 3-year follow-up study, high doses of vitamin E (2,000 IU per day) was reported to have no benefit in subjects with MCI (114). The lack of efficacy of vitamin E to prevent the progression of MCI to AD indicates that a single supplementary vitamin has no significant effect in the secondary prevention of AD, which is consistent with the previous cohort studies on the progression of the cognitively normal elderly to AD.

Table 4
Table 4
Image Tools

In contrast to the MCI trial, in a double-blind, placebo-controlled, randomized, multicenter 2-year study, 2,000 IU per day of vitamin E has been shown to slow progression in patients with moderate AD (109). Vitamin E significantly delayed the time to the primary outcome (death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia), whereas it did not slow the rate of decline on cognitive functioning assessed by the Alzheimer Disease Assessment Scale or the Mini-Mental State Examination. Although not only vitamin E, but also a selective monoamine oxidase B inhibitor, selegiline, or a combination of vitamin E and selegiline was found to have a similar beneficial effect in this study, vitamin E has been widely used for patients with AD because of its low cost and perceived safety, as current practice guidelines recommend (121, 122). However, the safety of high-dosage or long-term supplementation of vitamin E has recently been called into question. Indeed, a meta-analysis with vitamin E dosage varied between 16.5 and 2,000 IU per day and average follow-up period ranged from 1.4 to 8.2 years suggested that high-dosage (daily dose of 400 IU and over) of vitamin E supplements may increase all-cause mortality (123). Moreover, long-term supplementation (median follow-up period of 7.0 years) of vitamin E with daily dose of 400 IU may increase the risk for heart failure in patients with vascular disease or diabetes mellitus (124). Together with the increased all-cause mortality associated with high dosages of β-carotene (125) and the increased risk of cardiovascular disease mortality with high dosages of vitamin C in postmenopausal women with diabetes (126), use of any high-dosage vitamin supplements should be discouraged until evidence of efficacy is documented from appropriately designed clinical trials. Of note, vitamins E and C, carotenoids, and flavonoids may lose their effectiveness as antioxidants or even act as prooxidants under certain circumstances in vitro, for example, at high concentration or high partial pressures of oxygen, in the presence of metal ions such as copper or iron, under mild oxidative condition without coantioxidants, and at a high concentration of carotenoid itself (127-130).

Back to Top | Article Outline
Antioxidant Strategy for Alzheimer Disease: Targeting Modifiable Risk Factors

When we consider the highly complex system for the fine regulation of cellular redox balance in the human body, it is no wonder that extrinsic in vitro antioxidants may show only limited effects on reduction of oxidative damage in biologic systems. Therefore, we should survey ways to activate our intrinsic system to reduce oxidative damage, which might be effective in the retardation of disease progression, at least in subclinical and early-stage AD. If the process of Aβ deposition is closely associated with antioxidant function, as we have discussed in this review, this process will be activated during times when oxidative stress is high and the endogenous antioxidant defenses are compromised. On the other hand, if this system is efficient and/or is supported by exogenous antioxidant supplementation, the antioxidant effects of Aβ may not be necessary. Indeed, several substances such as vitamin E, nonsteroidal antiinflammatory drugs, the metal chelator clioquinol, copper (stabilizing copper/zinc SOD), melatonin, omega-3 polyunsaturated fatty acid (docosahexaenoic acid), and the curry spice curcumin reduce the levels of Aβ and/or Aβ deposition in brains of a transgenic animal model of AD (80, 81, 131-137) (Table 5). Because all these substances are antioxidants (59, 60, 81, 131-133), they constitute potential candidates in an antioxidative strategy for treatment of AD. However, as we have learned from the vitamin E studies, each of them alone may only show limited clinical benefit despite their dramatic effect under experimental conditions.

Table 5
Table 5
Image Tools

It is well established that experimental animals on caloric restriction that lowers steady-state levels of oxidative stress show several signs of retarded aging (138, 139). Recently, the association between caloric intake and the risk of AD was analyzed (44, 140). Compared with individuals in the lowest quartile of total caloric intake or fat intake, those in the highest quartile had an increased risk of AD. This increased risk was significant only among individuals carrying APOE ε4 allele. The hazard ratios of AD for total caloric intake and fats intake are 2.27 and 2.31, respectively (44). Of note, caloric restriction attenuates Aβ deposition in AβPP transgenic mice, which is achieved by feeding 60% or 70% of the calories consumed by the pair-controlled ad libitum diet (141, 142). Indeed, it has been suggested that a daily calorie intake in range of 1,800 to 2,200 for moderately active adults may dramatically reduce the risk of AD, Parkinson disease, and stroke (63).

A lifestyle-related factor other than diet (i.e. inactivity) is considered to be a risk factor of AD. When activities were evaluated by using a scale in terms of "diversity" (total numbers of activities) and "intensity" (hours per month), the scores were significantly lower in passive diversity, intellectual diversity, and physical diversity as well as intellectual intensity in early and middle adulthood (from ages 20 to 60 years) of the patients with AD (45). In the Canadian Study of Health and Aging, a large-scale prospective cohort of 9,008 subjects aged 65 years or older, physical activity was associated with lower risks of cognitive impairment, AD, and dementia of any types (143). Participation in leisure activities, including intellectual and physical activities, was associated with a reduced risk of development of both AD and vascular dementia in a prospective cohort of 469 subjects aged 75 years or older (144). In another large-scale prospective cohort of 3,375 subjects aged 65 years or older, an inverse association between physical activity and risk for AD or vascular dementia was identified among APOE ε4 noncarriers but not APOE ε4 carriers (145). This study also suggested that participating in a number of different activities may be as or more important than frequency, intensity, and duration of physical activity with respect to dementia risk. Exercise is effective not only in the stages of primary and secondary prevention, but also in symptomatic treatment for AD. A randomized, controlled trial of 153 patients with AD demonstrated that exercise combined with teaching caregivers behavioral management techniques improved the physical health and depression of patients with AD (146). In AβPP/PS-1 double transgenic mice, environmental enrichment reduced Aβ deposition, which was striking in enriched mice exhibiting high activity levels (percent time running) (147). Another transgenic model with a double-mutant form of AβPP also showed reduced Aβ deposition by 5 months of voluntary exercise (148). Importantly, experimental studies indicate that an activation of an intrinsic antioxidant defense system is involved in the mechanisms by which caloric restriction, intellectual activity, and exercise promote neuronal survival. Each of them induces a mild cellular stress response, and consequently neurons respond to these stresses by activating signaling pathways that produce growth factors and protein chaperones, which is followed by the production of antioxidant enzymes such as copper/zinc SOD, manganese SOD, glutathione peroxidase, and catalase (14).

In summary, daily diet and activity may be important targets in the antioxidative strategy for the prevention and treatment of AD. Clearly, further studies are required to establish the regimens for the practical intervention at each stage of AD.

Back to Top | Article Outline

CONCLUSION

Most of the known genetic, medical, environmental, and lifestyle-related factors for AD are associated with increased oxidative stress. In concord, human cases at the preclinical stage of AD (e.g. subjects with MCI, young adults with Down syndrome as well as cellular and animal models of AD) provide consistent evidence that oxidative insult is a significant early event in the pathologic cascade of AD. Contrary to the general accepted role of the pathologic hallmarks, the process of aggregation of Aβ and tau proteins may be involved in a compensatory, protective response to oxidative insult. Focusing on recently reported modifiable risk factors for AD, we suspect that maintaining a low-calorie diet as well as intellectual and physical activities represents an important antioxidative strategy for the prevention of AD.

Back to Top | Article Outline

REFERENCES

1. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 2000;1502:139-44

2. Raina AK, Hochman A, Zhu X, et al. Abortive apoptosis in Alzheimer's disease. Acta Neuropathol (Berl) 2001;101:305-10

3. Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci 2003;23:2557-63

4. Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005;25:5446-54

5. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 1997;94:9866-68

6. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998;158:47-52

7. Castellani RJ, Siedlak SL, Perry G, Smith MA. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol (Berl) 2000;100:111-14

8. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: A central role for bound transition metals. J Neurochem 2000;74:270-79

9. Dong J, Atwood CS, Anderson VE, et al. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 2003;42:2768-73

10. Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 1999;58:188-97

11. Manning-Bog AB, McCormack AL, Purisai MG, Bolin LM, Di Monte DA. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 2003;23:3095-99

12. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004;431:805-10

13. Hy LX, Keller DM. Prevalence of AD among whites: A summary by levels of severity. Neurology 2000;55:198-204

14. Mattson MP, Chan SL, Duan W. Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol Rev 2002;82:637-72

15. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-95

16. Floyd RA, Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 2002;23:795-807

17. Eckert A, Steiner B, Marques C, et al. Elevated vulnerability to oxidative stress-induced cell death and activation of caspase-3 by the Swedish amyloid precursor protein mutation. J Neurosci Res 2001;64:183-92

18. Hashimoto M, Hsu LJ, Rockenstein E, Takenouchi T, Mallory M, Masliah E. alpha-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J Biol Chem 2002;277:11465-72

19. Marques CA, Keil U, Bonert A, et al. Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: Oxidative stress, caspases, and the JNK pathway. J Biol Chem 2003;278:28294-302

20. Guo Q, Sopher BL, Furukawa K, et al. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: Involvement of calcium and oxyradicals. J Neurosci 1997;17:4212-22

21. Smith MA, Hirai K, Hsiao K, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998;70:2212-15

22. Guo Q, Sebastian L, Sopher BL, et al. Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: Central roles of superoxide production and caspase activation. J Neurochem 1999;72:1019-29

23. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001;21:4183-87

24. Leutner S, Czech C, Schindowski K, Touchet N, Eckert A, Muller WE. Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations. Neurosci Lett 2000;292:87-90

25. Takahashi M, Dore S, Ferris CD, et al. Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron 2000;28:461-73

26. Matsuoka Y, Picciano M, La Francois J, Duff K. Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience 2001;104:609-13

27. LaFontaine MA, Mattson MP, Butterfield DA. Oxidative stress in synaptosomal proteins from mutant presenilin-1 knock-in mice: Implications for familial Alzheimer's disease. Neurochem Res 2002;27:417-21

28. Schuessel K, Frey C, Jourdan C, et al. Aging sensitizes toward ROS formation and lipid peroxidation in PS1M146L transgenic mice. Free Radic Biol Med 2006;40:850-62

29. Cecchi C, Fiorillo C, Sorbi S, et al. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med 2002;33:1372-79

30. Nunomura A, Chiba S, Lippa CF, et al. Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. Neurobiol Dis 2004;17:108-13

31. Bogdanovic N, Zilmer M, Zilmer K, Rehema A, Karelson E. The Swedish APP670/671 Alzheimer's disease mutation: The first evidence for strikingly increased oxidative injury in the temporal inferior cortex. Dement Geriatr Cogn Disord 2001;12:364-70

32. Saunders AM, Schmader K, Breitner JC, et al. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 1993;342:710-11

33. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14:55-61

34. Tamaoka A, Miyatake F, Matsuno S, et al. Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease. Neurology 2000;54:2319-21

35. Montine KS, Reich E, Neely MD, et al. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J Neuropathol Exp Neurol 1998;57:415-25

36. Ramassamy C, Averill D, Beffert U, et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med 1999;27:544-53

37. Leibson CL, Rocca WA, Hanson VA, et al. Risk of dementia among persons with diabetes mellitus: A population-based cohort study. Am J Epidemiol 1997;145:301-308

38. Guo Z, Cupples LA, Kurz A, et al. Head injury and the risk of AD in the MIRAGE study. Neurology 2000;54:1316-23

39. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002;137:149-55

40. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-83

41. Honig LS, Tang MX, Albert S, et al. Stroke and the risk of Alzheimer disease. Arch Neurol 2003;60:1707-12

42. Ott A, Slooter AJ, Hofman A, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: The Rotterdam Study. Lancet 1998;351:1840-43

43. Rondeau V, Commenges D, Jacqmin-Gadda H, Dartigues JF. Relation between aluminum concentrations in drinking water and Alzheimer's disease: An 8-year follow-up study. Am J Epidemiol 2000;152:59-66

44. Luchsinger JA, Tang MX, Shea S, Mayeux R. Caloric intake and the risk of Alzheimer disease. Arch Neurol 2002;59:1258-63

45. Friedland RP, Fritsch T, Smyth KA, et al. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members. Proc Natl Acad Sci U S A 2001;98:3440-45

46. Gupta VB, Anitha S, Hegde ML, et al. Aluminium in Alzheimer's disease: Are we still at a crossroad? Cell Mol Life Sci 2005;62:143-58

47. Bramlett HM, Dietrich WD. Pathophysiology of cerebral ischemia and brain trauma: Similarities and differences. J Cereb Blood Flow Metab 2004;24:133-50

48. Perna AF, Ingrosso D, De Santo NG. Homocysteine and oxidative stress. Amino Acids 2003;25:409-17

49. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol 2003;17:24-38

50. Moriel P, Plavnik FL, Zanella MT, Bertolami MC, Abdalla DS. Lipid peroxidation and antioxidants in hyperlipidemia and hypertension. Biol Res 2000;33:105-12

51. Preston AM. Cigarette smoking-Nutritional implications. Prog Food Nutr Sci 1991;15:183-217

52. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002;287:3223-29

53. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32

54. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43

55. in t' Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-21

56. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003;60:940-46

57. Truelsen T, Thudium D, Gronbaek M. Amount and type of alcohol and risk of dementia: The Copenhagen City Heart Study. Neurology 2002;59:1313-19

58. Behl C, Skutella T, Lezoualc'h F, et al. Neuroprotection against oxidative stress by estrogens: Structure-activity relationship. Mol Pharmacol 1997;51:535-41

59. Hamburger SA, McCay PB. Spin trapping of ibuprofen radicals: Evidence that ibuprofen is a hydroxyl radical scavenger. Free Radic Res Commun 1990;9:337-42

60. Green P, Glozman S, Weiner L, Yavin E. Enhanced free radical scavenging and decreased lipid peroxidation in the rat fetal brain after treatment with ethyl docosahexaenoate. Biochim Biophys Acta 2001;1532:203-12

61. Echeverry C, Blasina F, Arredondo F, et al. Cytoprotection by neutral fraction of tannat red wine against oxidative stress-induced cell death. J Agric Food Chem 2004;52:7395-99

62. Stoll LL, McCormick ML, Denning GM, Weintraub NL. Antioxidant effects of statins. Drugs Today (Barc) 2004;40:975-90

63. Mattson MP, Duan W, Guo Z. Meal size and frequency affect neuronal plasticity and vulnerability to disease: Cellular and molecular mechanisms. J Neurochem 2003;84:417-31

64. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:759-67

65. Nunomura A, Perry G, Pappolla MA, et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 2000;59:1011-17

66. Abe T, Tohgi H, Isobe C, Murata T, Sato C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J Neurosci Res 2002;70:447-50

67. Ding Q, Markesbery WR, Chen Q, Li F, Keller JN. Ribosome dysfunction is an early event in Alzheimer's disease. J Neurosci 2005;25:9171-75

68. Keller JN, Schmitt FA, Scheff SW, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005;64:1152-56

69. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Arch Neurol 2002;59:972-76

70. Migliore L, Fontana I, Trippi F, et al. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 2005;26:567-73

71. Rinaldi P, Polidori MC, Metastasio A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 2003;24:915-19

72. Guidi I, Galimberti D, Lonati S, et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2006;27:262-69

73. Schipper HM, Bennett DA, Liberman A, et al. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol Aging 2006;27:252-61

74. Drake J, Link CD, Butterfield DA. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging 2003;24:415-20

75. Schuessel K, Schafer S, Bayer TA, et al. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol Dis 2005;18:89-99

76. Misonou H, Morishima-Kawashima M, Ihara Y. Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry 2000;39:6951-59

77. Paola D, Domenicotti C, Nitti M, et al. Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem Biophys Res Commun 2000;268:642-46

78. Gomez-Ramos A, Diaz-Nido J, Smith MA, Perry G, Avila J. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 2003;71:863-70

79. Nakashima H, Ishihara T, Yokota O, et al. Effects of alpha-tocopherol on an animal model of tauopathies. Free Radic Biol Med 2004;37:176-86

80. Sung S, Yao Y, Uryu K, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. Faseb J 2004;18:323-25

81. Bayer TA, Schafer S, Simons A, et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci U S A 2003;100:14187-92

82. Li F, Calingasan NY, Yu F, et al. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem 2004;89:1308-12

83. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal 2000;2:413-20

84. Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001;21:3017-23

85. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94

86. Honda K, Smith MA, Zhu X, et al. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem 2005;280:20978-86

87. Reddy PH, McWeeney S, Park BS, et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: Up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet 2004;13:1225-40

88. Maynard CJ, Caai R, Volitakis I, et al. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 2002;277:44670-76

89. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 2002;9:61-68

90. Walsh DM, Selkoe DJ. Oligomers on the brain: The emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004;11:213-28

91. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003;26:267-98

92. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999;58:376-88

93. Neve RL, Robakis NK. Alzheimer's disease: A re-examination of the amyloid hypothesis. Trends Neurosci 1998;21:15-19

94. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997;56:965-73

95. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997;41:17-24

96. Cras P, Smith MA, Richey PL, Siedlak SL, Mulvihill P, Perry G. Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol (Berl) 1995;89:291-95

97. Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005;309:476-81

98. Cash AD, Aliev G, Siedlak SL, et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 2003;162:1623-27

99. Kontush A, Berndt C, Weber W, et al. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med 2001;30:119-28

100. Zou K, Gong JS, Yanagisawa K, Michikawa M. A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 2002;22:4833-41

101. Bishop GM, Robinson SR. Human Abeta1-42 reduces iron-induced toxicity in rat cerebral cortex. J Neurosci Res 2003;73:316-23

102. Cuajungco MP, Goldstein LE, Nunomura A, et al. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 2000;275:19439-42

103. Lee HG, Perry G, Moreira PI, et al. Tau phosphorylation in Alzheimer's disease: Pathogen or protector? Trends Mol Med 2005;11:164-69

104. Liu Q, Smith MA, Avila J, et al. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med 2005;38:746-54

105. Takeda A, Smith MA, Avila J, et al. In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J Neurochem 2000;75:1234-41

106. Sano M. Noncholinergic treatment options for Alzheimer's disease. J Clin Psychiatry 2003;64(suppl 9):23-28

107. Willcox JK, Ash SL, Catignani GL. Antioxidants and prevention of chronic disease. Crit Rev Food Sci Nutr 2004;44:275-95

108. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 2003;60:1685-91

109. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22

110. Morris MC, Evans DA, Bienias JL, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002;287:3230-37

111. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol 2004;61:82-88

112. Luchsinger JA, Tang MX, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60:203-208

113. Laurin D, Masaki KH, Foley DJ, White LR, Launer LJ. Midlife dietary intake of antioxidants and risk of late-life incident dementia: The Honolulu-Asia Aging Study. Am J Epidemiol 2004;159:959-67

114. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-88

115. Veinbergs I, Mallory M, Sagara Y, Masliah E. Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice. Eur J Neurosci 2000;12:45414-16

116. Perkins AJ, Hendrie HC, Callahan CM, et al. Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am J Epidemiol 1999;150:37-44

117. Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000;54:1265-72

118. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. Vitamin E and cognitive decline in older persons. Arch Neurol 2002;59:1125-32

119. Grodstein F, Chen J, Willett WC. High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am J Clin Nutr 2003;77:975-84

120. Morris MC, Evans DA, Tangney CC, et al. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr 2005;81:508-14

121. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Alzheimer's Disease and Other Dementias of Late Life, 1st ed. American Psychiatric Publishing, 1997

122. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66

123. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46

124. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA 2005;293:1338-47

125. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: Meta-analysis of randomised trials. Lancet 2003;361:2017-23

126. Lee DH, Folsom AR, Harnack L, Halliwell B, Jacobs DR Jr. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr 2004;80:1194-200

127. Kontush A, Finckh B, Karten B, Kohlschutter A, Beisiegel U. Antioxidant and prooxidant activity of alpha-tocopherol in human plasma and low density lipoprotein. J Lipid Res 1996;37:1436-48

128. Otero P, Viana M, Herrera E, Bonet B. Antioxidant and prooxidant effects of ascorbic acid, dehydroascorbic acid and flavonoids on LDL submitted to different degrees of oxidation. Free Radic Res 1997;27:619-26

129. Sugihara N, Arakawa T, Ohnishi M, Furuno K. Anti- and pro-oxidative effects of flavonoids on metal-induced lipid hydroperoxide-dependent lipid peroxidation in cultured hepatocytes loaded with alpha-linolenic acid. Free Radic Biol Med 1999;27:1313-23

130. Zhang P, Omaye ST. Antioxidant and prooxidant roles for beta-carotene, alpha-tocopherol and ascorbic acid in human lung cells. Toxicol In Vitro 2001;15:13-24

131. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21:8370-77

132. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-76

133. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 2003;85:1101-108

134. Lim GP, Calon F, Morihara T, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005;25:3032-40

135. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000;20:5709-14

136. Jantzen PT, Connor KE, DiCarlo G, et al. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002;22:2246-54

137. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892-901

138. Roth GS, Ingram DK, Lane MA. Slowing ageing by caloric restriction. Nat Med 1995;1:414-15

139. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science 1996;273:59-63

140. Smith MA, Petot GJ, Perry G. Diet and oxidative stress: A novel synthesis of epidemiological data on Alzheimer's disease. J Alzheimers Dis 1999;1:203-206

141. Wang J, Ho L, Qin W, et al. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. Faseb J 2005;19:659-61

142. Patel NV, Gordon MN, Connor KE, et al. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol Aging 2005;26:995-1000

143. Laurin D, Verreault R, Lindsay J, MacPherson K, Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 2001;58:498-504

144. Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003;348:2508-16

145. Podewils LJ, Guallar E, Kuller LH, et al. Physical activity, APOE genotype, and dementia risk: Findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 2005;161:639-51

146. Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: A randomized controlled trial. JAMA 2003;290:2015-22

147. Lazarov O, Robinson J, Tang YP, et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 2005;120:701-13

148. Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci 2005;25:4217-21

Cited By:

This article has been cited 97 time(s).

Biochimica Et Biophysica Acta-Molecular Basis of Disease
Alzheimer disease, the two-hit hypothesis: An update
Zhu, XW; Lee, HG; Perry, G; Smith, MA
Biochimica Et Biophysica Acta-Molecular Basis of Disease, 1772(4): 494-502.
10.1016/j.bbadis.2006.10.014
CrossRef
Journal of Alzheimers Disease
Herpes simplex virus type 1 in Alzheimer's disease: The enemy within
Itzhaki, RF; Wozniak, MA
Journal of Alzheimers Disease, 13(4): 393-405.

Biochimica Et Biophysica Acta-General Subjects
Emerging potential of thioredoxin and thioredoxin interacting proteins in various disease conditions
Maulik, N; Das, DK
Biochimica Et Biophysica Acta-General Subjects, 1780(): 1368-1382.
10.1016/j.bbagen.2007.12.008
CrossRef
Biochimica Et Biophysica Acta-Proteins and Proteomics
Polyphenol-induced dissociation of various amyloid fibrils results in a methionine-independent formation of ROS
Shoval, H; Weiner, L; Gazit, E; Levy, M; Pinchuk, I; Lichtenberg, D
Biochimica Et Biophysica Acta-Proteins and Proteomics, 1784(): 1570-1577.
10.1016/j.bbapap.2008.08.007
CrossRef
Free Radical Research
Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease
Siedlak, SL; Casadesus, G; Webber, KM; Pappolla, MA; Atwood, CS; Smith, MA; Perry, G
Free Radical Research, 43(2): 156-164.
10.1080/10715760802644694
CrossRef
Neuroscience Research
Amyloid-beta(25-35) impairs memory and increases NO in the temporal cortex of rats
Limo, ID; Diaz, A; Mendieta, L; Chamorro, G; Espinosa, B; Zenteno, E; Guevara, J
Neuroscience Research, 63(2): 129-137.
10.1016/j.neures.2008.11.006
CrossRef
Journal of Neuroscience Research
c-Jun phosphorylation in Alzheimer disease
Thakur, A; Wang, XL; Siedlak, SL; Perry, G; Smith, MA; Zhu, XW
Journal of Neuroscience Research, 85(8): 1668-1673.
10.1002/jnr.21298
CrossRef
Journal of Alzheimers Disease
Phosphorylated tau: Toxic, protective, or none of the above
Castellani, RJ; Nunomura, A; Lee, HG; Perry, G; Smith, MA
Journal of Alzheimers Disease, 14(4): 377-383.

Journal of Neural Transmission
Recent advances in our understanding of neurodegeneration
Jellinger, KA
Journal of Neural Transmission, 116(9): 1111-1162.
10.1007/s00702-009-0240-y
CrossRef
Brain Pathology
Mitochondrial ATP-Synthase in the Entorhinal Cortex Is a Target of Oxidative Stress at Stages I/II of Alzheimer's Disease Pathology
Terni, B; Boada, J; Portero-Otin, M; Pamplona, R; Ferrer, I
Brain Pathology, 20(1): 222-233.
10.1111/j.1750-3639.2009.00266.x
CrossRef
Gerontology
Inhibition of iron-catalyzed oxidations by attainable uric acid and ascorbic acid levels: Therapeutic implications for Alzheimer's disease and late cognitive impairment
Waugh, WH
Gerontology, 54(4): 238-243.
10.1159/000122618
CrossRef
Aging Cell
Oxidative stress increases levels of endogenous amyloid-beta peptides secreted from primary chick brain neurons
Goldsbury, C; Whiteman, IT; Jeong, EV; Lim, YA
Aging Cell, 7(5): 771-775.
10.1111/j.1474-9726.2008.00423.x
CrossRef
International Journal of Molecular Sciences
Molecular Pathogenesis of Alzheimer's Disease: Reductionist versus Expansionist Approaches
Castellani, RJ; Zhu, XW; Lee, HG; Smith, MA; Perry, G
International Journal of Molecular Sciences, 10(3): 1386-1406.
10.3390/ijms10031386
CrossRef
Taiwanese Journal of Obstetrics & Gynecology
Dual Action of Memantine in Alzheimer Disease: A Hypothesis
Wu, TY; Chen, CP
Taiwanese Journal of Obstetrics & Gynecology, 48(3): 273-277.

Metabolic Brain Disease
Proline impairs energy metabolism in cerebral cortex of young rats
Ferreira, AGK; Lima, DD; Delwing, D; Mackedanz, V; Tagliari, B; Kolling, J; Schuck, PF; Wajner, M; Wyse, ATS
Metabolic Brain Disease, 25(2): 161-168.
10.1007/s11011-010-9193-y
CrossRef
Archives of Internal Medicine
Cognitive declines therapy by iron burden reduction
Waugh, WH
Archives of Internal Medicine, 167(): 1098.

Revista Latinoamericana De Hipertension
Exploratory study into the behaviour of the lipidic profile, malondyaldehyde, and nitric oxide in the Yukpa ethnic group in the state of Zulia, Venezuela
Bermudez, V; Urribarri, J; Colmenares, C; Acosta, L; Rincon, L; Chacin, M; Viloria, A; Amell, A; Nunez, M; Souki, A; Seyfi, H; Perez, A; Medina, M; Cano, C
Revista Latinoamericana De Hipertension, 3(5): 148-152.

Gaceta Medica De Mexico
The effect of ibuprofen and acetylsalicylic acid on cognitive impairment, total antioxidant power and isoprostane serum
Ibanez-Hernandez, MG; Macias-Islas, MA; Zavalza-Gomez, AB; Pacheco-Moises, FP; Ortiz, GG
Gaceta Medica De Mexico, 144(6): 497-502.

Neuromolecular Medicine
Mitochondrial Medicine for Aging and Neurodegenerative Diseases
Reddy, PH
Neuromolecular Medicine, 10(4): 291-315.
10.1007/s12017-008-8044-z
CrossRef
Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis
Protective effect of creatine against RNA damage
Fimognari, C; Sestili, P; Lenzi, M; Cantelli-Forti, G; Hrelia, P
Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 670(): 59-67.
10.1016/j.mrfmmm.2009.07.005
CrossRef
Journal of Alzheimers Disease
Acetyl-L-Carnitine Attenuates Okadaic Acid Induced Tau Hyperphosphorylation and Spatial Memory Impairment in Rats
Yin, YY; Liu, H; Cong, XB; Liu, Z; Wang, Q; Wang, JZ; Zhu, LQ
Journal of Alzheimers Disease, 19(2): 735-746.
10.3233/JAD-2010-1272
CrossRef
Journal of Neuroscience Research
Progressive oxidative damage in the central nervous system of a murine model for juvenile batten disease
Benedict, JW; Sommers, CA; Pearce, DA
Journal of Neuroscience Research, 85(): 2882-2891.
10.1002/jnr.21416
CrossRef
Bioorganic Chemistry
Tacrine derivatives-acetylcholinesterase interaction: H-1 NMR relaxation study
Delfini, M; Di Cocco, ME; Piccioni, F; Porcelli, F; Borioni, A; Rodomonte, A; Del Giudice, MR
Bioorganic Chemistry, 35(3): 243-257.
10.1016/j.bioorg.2007.01.001
CrossRef
Journal of Neurochemistry
Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein
Tamagno, E; Guglielmotto, M; Aragno, M; Borghi, R; Autelli, R; Giliberto, L; Muraca, G; Danni, O; Zhu, XW; Smith, MA; Perry, G; Jo, DG; Mattson, MP; Tabaton, M
Journal of Neurochemistry, 104(3): 683-695.
10.1111/j.1471-4159.2007.05072.x
CrossRef
Journal of Neuroscience Research
Protective effect of prion protein via the N-terminal region in mediating a protective effect on paraquat-induced oxidative injury in neuronal cells
Dupiereux, I; Falisse-Poirrier, N; Zorzi, W; Watt, NT; Thellin, O; Zorzi, D; Pierard, O; Hooper, NM; Heinen, E; Elmoualij, B
Journal of Neuroscience Research, 86(3): 653-659.
10.1002/jnr.21506
CrossRef
Brain
Argyrophilic grain disease
Ferrer, I; Santpere, G; van Leeuwen, FW
Brain, 131(): 1416-1432.
10.1093/brain/awm305
CrossRef
Programmed Cell Death, General Principles for Studying Cell Death, Pt A
Oxidative lipidomics of programmed cell death
Tyurin, VA; Tyurina, YY; Kochanek, PM; Hamilton, R; DeKosky, ST; Greenberger, JS; Bayir, H; Kagan, VE
Programmed Cell Death, General Principles for Studying Cell Death, Pt A, 442(): 375-393.
10.1017/S0076-6879(08)01419-5
CrossRef
Acta Neuropathologica
RNA oxidation in Alzheimer disease and related neurodegenerative disorders
Nunomura, A; Hofer, T; Moreira, PI; Castellani, RJ; Smith, MA; Perry, G
Acta Neuropathologica, 118(1): 151-166.
10.1007/s00401-009-0508-1
CrossRef
Bioorganic & Medicinal Chemistry
Ganodermasides A and B, two novel anti-aging ergosterols from spores of a medicinal mushroom Ganoderma lucidum on yeast via UTH1 gene
Weng, YF; Xiang, L; Matsuura, A; Zhang, Y; Huang, QM; Qi, JH
Bioorganic & Medicinal Chemistry, 18(3): 999-1002.
10.1016/j.bmc.2009.12.070
CrossRef
Neurobiology of Aging
Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain
Simpson, JE; Ince, PG; Lace, G; Forster, G; Shaw, PJ; Matthews, F; Savva, G; Brayne, C; Wharton, SB
Neurobiology of Aging, 31(4): 578-590.
10.1016/j.neurobiolaging.2008.05.015
CrossRef
Free Radical Research
Specific reaction of Met 35 in amyloid beta peptide with hypochlorous acid
Nakamura, M; Shishido, N; Nunomura, A; Smith, MA; Perry, G; Akutsu, H; Hayashi, T
Free Radical Research, 44(7): 734-741.
10.3109/10715761003745954
CrossRef
Arzneimittel-Forschung-Drug Research
Investigation into the in vivo effects of five novel tacrine/ferulic acid and beta-carboline derivatives on scopolamine-induced cognitive impairment in rats using radial maze paradigm
Fleck, C; Appenroth, D; Fang, L; Schott, Y; Lehmann, J; Decker, M
Arzneimittel-Forschung-Drug Research, 60(6): 299-306.

Neurochemical Research
Oxidative Stress in Cerebrospinal Fluid of Patients with Aseptic and Bacterial Meningitis
de Menezes, CC; Dorneles, AG; Sperotto, RL; Duarte, MMF; Schetinger, MRC; Loro, VL
Neurochemical Research, 34(7): 1255-1260.
10.1007/s11064-008-9903-6
CrossRef
Current Medicinal Chemistry
Oxidative RNA damage and neurodegeneration
Nunomura, A; Moreira, PI; Takeda, A; Smith, MA; Perry, G
Current Medicinal Chemistry, 14(): 2968-2975.

Bioorganic & Medicinal Chemistry Letters
Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates
Fang, L; Kraus, B; Lehmann, J; Heilmann, J; Zhang, YH; Decker, M
Bioorganic & Medicinal Chemistry Letters, 18(9): 2905-2909.
10.1016/j.bmcl.2008.03.073
CrossRef
Ageing Research Reviews
Compromised respiratory adaptation and thermoregulation in aging and age-related diseases
Chan, SL; Wei, ZL; Chigurupati, S; Tu, WH
Ageing Research Reviews, 9(1): 20-40.
10.1016/j.arr.2009.09.006
CrossRef
Journal of the American Geriatrics Society
Sleep-disordered breathing and cognition in older women
Spira, AP; Blackwell, T; Stone, KL; Redline, S; Cauley, JA; Ancoli-Israel, S; Yaffe, K
Journal of the American Geriatrics Society, 56(1): 45-50.
10.1111/j.1532-5415.2007.01506.x
CrossRef
European Biophysics Journal With Biophysics Letters
Twenty years of metallo-neurobiology: where to now?
Bush, AI; Curtain, CC
European Biophysics Journal With Biophysics Letters, 37(3): 241-245.
10.1007/s00249-007-0228-1
CrossRef
Molecular Neurobiology
Mitochondrial Dysfunction: Common Final Pathway in Brain Aging and Alzheimer's Disease-Therapeutic Aspects
Muller, WE; Eckert, A; Kurz, C; Eckert, GP; Leuner, K
Molecular Neurobiology, 41(): 159-171.
10.1007/s12035-010-8141-5
CrossRef
Coordination Chemistry Reviews
Metal based neurodegenerative diseases - From molecular mechanisms to therapeutic strategies
Crichton, RR; Dexter, DT; Ward, RJ
Coordination Chemistry Reviews, 252(): 1189-1199.
10.1016/j.ccr.2007.10.019
CrossRef
International Journal of Molecular Sciences
Sublethal RNA oxidation as a mechanism for neurodegenerative disease
Castellani, RJ; Nunomura, A; Rolston, RK; Moreira, PI; Takeda, A; Perry, G; Smith, MA
International Journal of Molecular Sciences, 9(5): 789-806.
10.3390/ijms9050789
CrossRef
Parkinsonism & Related Disorders
Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease
Alvira, D; Ferrer, I; Gutierrez-Cuesta, J; Garcia-Castro, B; Pallas, M; Camins, A
Parkinsonism & Related Disorders, 14(4): 309-313.
10.1016/j.parkreldis.2007.09.005
CrossRef
Journal of Clinical Investigation
Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress
Dorrell, MI; Aguilar, E; Jacobson, R; Yanes, O; Gariano, R; Heckenlively, J; Banin, E; Ramirez, GA; Gasmi, M; Bird, A; Siuzdak, G; Friedlander, M
Journal of Clinical Investigation, 119(3): 611-623.
10.1172/JCI35977
CrossRef
Biochemistry
Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron
Nakamura, M; Shishido, N; Nunomura, A; Smith, MA; Perry, G; Hayashi, Y; Nakayama, K; Hayashi, T
Biochemistry, 46(): 12737-12743.
10.1021/bi701079z
CrossRef
Archives of Biochemistry and Biophysics
Oxidized proteins: Intracellular distribution and recognition by the proteasome
Jung, T; Bader, N; Grune, T
Archives of Biochemistry and Biophysics, 462(2): 231-237.
10.1016/j.abb.2007.01.030
CrossRef
Peptides
Copper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma
Mare, S; Penugonda, S; Robinson, SM; Dohgu, S; Banks, WA; Ercal, N
Peptides, 28(7): 1424-1432.
10.1016/j.peptides.2007.05.007
CrossRef
Mitochondria and Oxidative Stress in Neurodegenerative Disorders
Evidence of Oxidative Stress in Alzheimer's Disease Brain and Antioxidant Therapy Lights and Shadows
Pratico, D
Mitochondria and Oxidative Stress in Neurodegenerative Disorders, 1147(): 70-78.
10.1196/annals.1427.010
CrossRef
Chemmedchem
Tacrine-Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties
Fernandez-Bachiller, MI; Perez, C; Campillo, NE; Paez, JA; Gonzalez-Munoz, GC; Usan, P; Garcia-Palomero, E; Lopez, MG; Villarroya, M; Garcia, AG; Martinez, A; Rodriguez-Franco, MI
Chemmedchem, 4(5): 828-841.
10.1002/cmdc.200800414
CrossRef
Toxicological Sciences
In Utero Exposure to Benzene Disrupts Fetal Hematopoietic Progenitor Cell Growth via Reactive Oxygen Species
Badham, HJ; Winn, LM
Toxicological Sciences, 113(1): 207-215.
10.1093/toxsci/kfp242
CrossRef
Journal of Nutrition Health & Aging
Iana task force on nutrition and cognitive decline with aging
Gillette-Guyonnet, S; Van Kan, GA; Andrieu, S; Barberger-Gateau, P; Berr, C; Bonnefoy, M; Dartigues, JF; De Groot, L; Ferry, M; Galan, P; Hercberg, S; Jeandel, C; Morris, MC; Nourhashemi, F; Payette, H; Poulain, JP; Portet, F; Roussel, AM; Ritz, P; Rolland, Y; Vellas, B
Journal of Nutrition Health & Aging, 11(2): 132-152.

Free Radical Biology and Medicine
Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age
Abdul, HM; Sultana, R; Clair, DKS; Markesbery, WR; Butterfield, DA
Free Radical Biology and Medicine, 45(): 1420-1425.
10.1016/j.freeradbiomed.2008.08.012
CrossRef
Bioscience Journal
Chronic Lithium Treatment Prevent Anxiety-Like Behavior Related to Dietary Restriction
Ferreira, FR; Spini, VBMG; Ribeiro, GDC; Paduani, GF
Bioscience Journal, 25(2): 131-138.

Angewandte Chemie-International Edition
Structural Studies of Copper(I) Complexes of Amyloid-beta Peptide Fragments: Formation of Two-Coordinate Bis(histidine) Complexes
Himes, RA; Park, GY; Siluvai, GS; Blackburn, NJ; Karlin, KD
Angewandte Chemie-International Edition, 47(): 9084-9087.
10.1002/anie.200803908
CrossRef
Social Studies of Science
Regulatory Objectivity in Action: Mild Cognitive Impairment and the Collective Production of Uncertainty
Moreira, T; May, C; Bond, J
Social Studies of Science, 39(5): 665-690.
10.1177/0306312709103481
CrossRef
Redox Report
Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress
Gonzalez-Cuyar, LF; Hunter, B; Harris, PLR; Perry, G; Smith, MA; Castellani, RJ
Redox Report, 12(3): 119-124.
10.1179/135100007X200173
CrossRef
Antioxidants & Redox Signaling
Mitochondrial dysfunction in aging and Alzheimer's disease: Strategies to protect neurons
Reddy, PH
Antioxidants & Redox Signaling, 9(): 1647-1658.
10.1089/ars.2007.1754
CrossRef
Pharmaceutical Biology
Phenolic constituents from Rhopalocnemis phalloides with DPPH radical scavenging activity
She, GM; Hu, JB; Zhang, YJ; Yang, CR
Pharmaceutical Biology, 48(1): 116-119.
10.3109/13880200903032757
CrossRef
Journal of Food Science
Polyphenolic Acids from Mint (the Aerial of Mentha haplocalyx Briq.) with DPPH Radical Scavenging Activity
She, GM; Xu, C; Liu, B; Shi, RB
Journal of Food Science, 75(4): C359-C362.
10.1111/j.1750-3841.2010.01603.x
CrossRef
Geriatrics & Gerontology International
Lipids' peroxidation markers in Alzheimer's disease and vascular dementia
Gustaw-Rothenberg, K; Kowalczuk, K; Stryjecka-Zimmer, M
Geriatrics & Gerontology International, 10(2): 161-166.
10.1111/j.1447-0594.2009.00571.x
CrossRef
Bioorganic & Medicinal Chemistry Letters
Novel mitochondria-localizing TEMPO derivative for measurement of cellular oxidative stress in mitochondria
Ban, S; Nakagawa, H; Suzuki, T; Miyata, N
Bioorganic & Medicinal Chemistry Letters, 17(7): 2055-2058.
10.1016/j.bincl.2007.01.011
CrossRef
Current Medicinal Chemistry
Manipulation of microglial activation as a therapeutic strategy in Alzheimer's disease
Shie, FS; Woltjer, RL
Current Medicinal Chemistry, 14(): 2865-2871.

Trends in Molecular Medicine
Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease
Reddy, PH; Beal, MF
Trends in Molecular Medicine, 14(2): 45-53.
10.1016/j.molmed.2007.12.002
CrossRef
Free Radical Biology and Medicine
Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models
Sonnen, JA; Breitner, JC; Lovell, MA; Markesbery, WR; Quinn, JF; Montine, TJ
Free Radical Biology and Medicine, 45(3): 219-230.
10.1016/j.freeradbiomed.2008.04.022
CrossRef
Molecular Mechanisms of Xeroderma Pigmentosum
Roles of oxidative stress in xeroderma pigmentosum
Hayashi, M
Molecular Mechanisms of Xeroderma Pigmentosum, 637(): 120-127.

Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis
RNA as a new target for toxic and protective agents
Fimognari, C; Sestili, P; Lenzi, M; Bucchini, A; Cantelli-Forti, G; Hrelia, P
Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 648(): 15-22.
10.1016/j.mrfmmm.2008.09.003
CrossRef
Aging Cell
A free radical-generating system induces the cholesterol biosynthesis pathway: a role in Alzheimer's disease
Recuero, M; Vicente, MC; Martinez-Garcia, A; Ramos, MC; Carmona-Saez, P; Sastre, I; Aldudo, J; Vilella, E; Frank, A; Bullido, MJ; Valdivieso, F
Aging Cell, 8(2): 128-139.
10.1111/j.1474-9726.2009.00457.x
CrossRef
Natural Product Communications
Ingredients for Functional Drinks in Neurodegenerative Diseases: a Review
Zafrilla, P; Morillas, JM; Rubio-Perez, JM; Villar, EC
Natural Product Communications, 4(5): 719-740.

Neurology
Predictors of maintaining cognitive function in older adults The Health ABC Study
Yaffe, K; Fiocco, AJ; Lindquist, K; Vittinghoff, E; Simonsick, EM; Newman, AB; Satterfield, S; Rosano, C; Rubin, SM; Ayonayon, HN; Harris, TB
Neurology, 72(): 2029-2035.

Toxicologic Pathology
Long-term Air Pollution Exposure Is Associated with Neuroinflammation, an Altered Innate Immune Response, Disruption of the Blood-Brain Barrier, Ultrafine Particulate Deposition, and Accumulation of Amyloid beta-42 and alpha-Synuclein in Children and Young Adults
Calderon-Garciduenas, L; Solt, AC; Henriquez-Roldan, C; Torres-Jardon, R; Nuse, B; Herritt, L; Villarreal-Calderon, R; Osnaya, N; Stone, I; Garcia, R; Brooks, DM; Gonzalez-Maciel, A; Reynoso-Robles, R; Delgado-Chavez, R; Reed, W
Toxicologic Pathology, 36(2): 289-310.
10.1177/0192623307313011
CrossRef
Journal of Medicinal Food
Neuroprotective Activity of Vitis thunbergii var. taiwaniana Extracts In Vitro and In Vivo
Wang, CK; Chen, LG; Wen, CL; Hou, WC; Hung, LF; Yen, SJ; Shen, YJ; Lin, SY; Liang, YC
Journal of Medicinal Food, 13(1): 170-178.
10.1089/jmf.2009.1162
CrossRef
Neurobiology of Disease
Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease
Nunomura, A; Tamaoki, T; Tanaka, K; Motohashi, N; Nakamura, M; Hayashi, T; Yamaguchi, H; Shimohama, S; Lee, HG; Zhu, XW; Smith, MA; Perry, G
Neurobiology of Disease, 37(3): 731-737.
10.1016/j.nbd.2009.12.012
CrossRef
Journal of Alzheimers Disease
Antioxidants in Central Nervous System Diseases: Preclinical Promise and Translational Challenges
Kamat, CD; Gadal, S; Mhatre, M; Williamson, KS; Pye, QN; Hensley, K
Journal of Alzheimers Disease, 15(3): 473-493.

Neurochemical Research
Brain Oxidative Stress as Basic Target of Antioxidant Traditional Oriental Medicines
Konishi, T
Neurochemical Research, 34(4): 711-716.
10.1007/s11064-008-9872-9
CrossRef
Brain Pathology
Protein Targets of Oxidative Damage in Human Neurodegenerative Diseases with Abnormal Protein Aggregates
Martinez, A; Portero-Otin, M; Pamplona, R; Ferrer, I
Brain Pathology, 20(2): 281-297.
10.1111/j.1750-3639.2009.00326.x
CrossRef
Antioxidants & Redox Signaling
Mitochondrial dysfunction: The first domino in brain aging and Alzheimer's disease?
Leuner, K; Hauptmann, S; Abdel-Kader, R; Scherping, I; Keil, U; Strosznajder, JB; Eckert, A; Muller, WE
Antioxidants & Redox Signaling, 9(): 1659-1675.
10.1089/ars.2007.1763
CrossRef
Proceedings of the National Academy of Sciences of the United States of America
Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins
Wang, XL; Su, B; Siedlak, SL; Moreira, PI; Fujioka, H; Wang, Y; Casadesus, G; Zhu, XW
Proceedings of the National Academy of Sciences of the United States of America, 105(): 19318-19323.
10.1073/pnas.0804871105
CrossRef
Brain Research Bulletin
Abundant expression of zinc transporters in the amyloid plaques of Alzheimer's disease brain
Zhang, LH; Wang, X; Stoltenberg, M; Danscher, G; Huang, LP; Wang, ZY
Brain Research Bulletin, 77(1): 55-60.
10.1016/j.brainresbull.2008.03.014
CrossRef
Neuropathology
Oxidative stress in developmental brain disorders
Hayashi, M
Neuropathology, 29(1): 1-8.
10.1111/j.1440-1789.2008.00888.x
CrossRef
Chembiochem
Electrochemical and Conformational Consequences of Copper (Cu-I and Cu-II) Binding to beta-Amyloid(1-40)
Brzyska, M; Trzesniewska, K; Wieckowska, A; Szczepankiewicz, A; Elbaum, D
Chembiochem, 10(6): 1045-1055.
10.1002/cbic.200800732
CrossRef
Brain Pathology
Reduction of Cerebral Oxidative Stress Following Environmental Enrichment in Mice with Alzheimer-Like Pathology
Herring, A; Blome, M; Ambree, O; Sachser, N; Paulus, W; Keyvani, K
Brain Pathology, 20(1): 166-175.
10.1111/j.1750-3639.2008.00257.x
CrossRef
Bmc Medical Genomics
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases
Kell, DB
Bmc Medical Genomics, 2(): -.
ARTN 2
CrossRef
Neuropathology and Applied Neurobiology
Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer-type pathology in the ageing brain
Simpson, JE; Ince, PG; Haynes, LJ; Theaker, R; Gelsthorpe, C; Baxter, L; Forster, G; Lace, GL; Shaw, PJ; Matthews, FE; Savva, GM; Brayne, C; Wharton, SB
Neuropathology and Applied Neurobiology, 36(1): 25-40.
10.1111/j.1365-2990.2009.01030.x
CrossRef
Toxicology and Applied Pharmacology
In utero and in vitro effects of benzene and its metabolites on erythroid differentiation and the role of reactive oxygen species
Badham, HJ; Winn, LM
Toxicology and Applied Pharmacology, 244(3): 273-279.
10.1016/j.taap.2010.01.002
CrossRef
Experimental Gerontology
Association of cognitive function with serum uric acid level among Chinese nonagenarians and centenarians
Li, J; Dong, BR; Lin, P; Zhang, J; Liu, GJ
Experimental Gerontology, 45(5): 331-335.
10.1016/j.exger.2010.01.005
CrossRef
Expert Opinion on Investigational Drugs
Looking for novel ways to treat the hallmarks of Alzheimer's disease
Stewart, AJ; Fox, A; Morimoto, BH; Gozes, I
Expert Opinion on Investigational Drugs, 16(8): 1183-1196.
10.1517/13543784.16.8.1183
CrossRef
Journal of Alzheimers Disease
Nanotechnology solutions for Alzheimer's disease: Advances in research tools, diagnostic methods and therapeutic agents
Nazem, A; Mansoori, GA
Journal of Alzheimers Disease, 13(2): 199-223.

Free Radical Biology and Medicine
Nucleic acid oxidation in Alzheimer disease
Morelra, PI; Nunomura, A; Nakamura, M; Takeda, A; Shenk, JC; Aliev, G; Smith, MA; Perry, G
Free Radical Biology and Medicine, 44(8): 1493-1505.
10.1016/j.freeradbiomed.2008.01.002
CrossRef
Cell and Tissue Banking
Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies
Ferrer, I; Martinez, A; Boluda, S; Parchi, P; Barrachina, M
Cell and Tissue Banking, 9(3): 181-194.
10.1007/s10561-008-9077-0
CrossRef
Current Hypotheses and Research Milestones in Alzheimer's Disease
Neurofibrillary Tangle Formation as a Protective Response to Oxidative Stress in Alzheimer's Disease
Nunomura, A; Takeda, A; Moreira, PI; Castellani, RJ; Lee, H; Zhu, XW; Smith, MA; Perry, G
Current Hypotheses and Research Milestones in Alzheimer's Disease, (): 103-113.

Neurobiology of Aging
Mitochondrial haplogroup H and Alzheimer's disease-Is there a connection?
Maruszak, A; Canter, JA; Styczynska, M; Zekanowski, C; Barcikowska, M
Neurobiology of Aging, 30(): 1749-1755.
10.1016/j.neurobiolaging.2008.01.004
CrossRef
Neuroscience
Oxidative damage of 14-3-3 zeta and gamma isoforms in Alzheimer's disease and cerebral amyloid angiopathy (Retracted article. See vol. 161, pg. 663, 2009)
Santpere, G; Puig, B; Ferrer, I
Neuroscience, 146(4): 1640-1651.
10.1016/j.neuroscience.2007.03.013
CrossRef
American Journal of Geriatric Psychiatry
Glutathione S-transferase P1 and T1 gene polymorphisms predict longitudinal course and age at onset of Alzheimer disease
Spalletta, G; Bernardini, S; Bellincampi, L; Federici, G; Trequattrini, A; Ciappi, F; Bria, P; Caltagirone, C; Bossu, P
American Journal of Geriatric Psychiatry, 15(): 879-887.

Journal of Alzheimers Disease
Chronic inflammation and amyloidogenesis in Alzheimer's disease - Role of spirochetes
Miklossy, J
Journal of Alzheimers Disease, 13(4): 381-391.

Chemical Research in Toxicology
Covalent Cross-Linking of Glutathione and Carnosine to Proteins by 4-Oxo-2-nonenal
Zhu, X; Gallogly, MM; Mieyal, JJ; Anderson, VE; Sayre, LM
Chemical Research in Toxicology, 22(6): 1050-1059.
10.1021/tx9000144
CrossRef
Alzheimer Disease & Associated Disorders
Luteinizing-hormone Releasing Hormone Therapy and the Risk of Death From Alzheimer Disease
D'Amico, AV; Braccioforte, MH; Moran, BJ; Chen, M
Alzheimer Disease & Associated Disorders, 24(1): 85-89.
10.1097/WAD.0b013e31819cb8f4
PDF (136) | CrossRef
Journal of Neuropathology & Experimental Neurology
RNA in Brain Disease: No Longer Just "The Messenger in the Middle"
Nelson, PT; Keller, JN
Journal of Neuropathology & Experimental Neurology, 66(6): 461-468.
10.1097/01.jnen.0000240474.27791.f3
PDF (150) | CrossRef
Journal of Neuropathology & Experimental Neurology
Alzheimer Disease Pathology As a Host Response
Castellani, RJ; Lee, H; Zhu, X; Perry, G; Smith, MA
Journal of Neuropathology & Experimental Neurology, 67(6): 523-531.
10.1097/NEN.0b013e318177eaf4
PDF (761) | CrossRef
Back to Top | Article Outline
Keywords:

Alzheimer disease; Antioxidant; Mild cognitive impairment; Oxidative stress; Prevention; Risk factor; Therapy

© 2006 American Association of Neuropathologists, Inc

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.